Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives

Zsolt Székelyhidi, János Pató, Frigyes Wáczek, Péter Bánhegyi, Bálint Hegymegi-Barakonyi, Dániel Eros, György Mészáros, Ferenc Hollósy, Doris Hafenbradl, Sabine Obert, Bert Klebl, György Kéri, László Orfi

Research output: Contribution to journalArticle

28 Citations (Scopus)


SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined Log P and Log S values.

Original languageEnglish
Pages (from-to)3241-3246
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Issue number13
Publication statusPublished - Jul 1 2005


  • Kinase inhibitor
  • Quinoxaline
  • SRPK-1

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives'. Together they form a unique fingerprint.

  • Cite this

    Székelyhidi, Z., Pató, J., Wáczek, F., Bánhegyi, P., Hegymegi-Barakonyi, B., Eros, D., Mészáros, G., Hollósy, F., Hafenbradl, D., Obert, S., Klebl, B., Kéri, G., & Orfi, L. (2005). Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives. Bioorganic and Medicinal Chemistry Letters, 15(13), 3241-3246.